fda on compounded tirzepatide says that the GLP-1 shortage is over FDA moves to remove GLP-1

The phone barely rings before going to a generic voicemail, and I never received a call back

By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29)

Lillys announcement is the latest in a string of proclamations by drug companies of plans for more US manufacturing capacity

I was refered by my hematologist whom I trust and respect

Retatrutide is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly

The last expiry date of these follow-on patents is November 22, 2040, 14 years after the expiration of the 208 patent covering the original compound